Zheng Quan Shi Bao·2025-12-01 12:35Core Viewpoint - TaiLong Pharmaceutical (600222) announced a suspension of trading due to potential changes in company control as its major shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd., is planning to transfer shares [2][4]. Group 1: Company Announcement - The trading suspension for TaiLong Pharmaceutical will begin on December 2, 2025, and is expected to last no more than two trading days [4]. - The company operates in the pharmaceutical manufacturing and research services sector, which includes four main business segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [4]. Group 2: Stock Performance - TaiLong Pharmaceutical's stock has shown strong performance this year, with a cumulative increase of nearly 70%, and a significant rise of approximately 25% in November alone [4]. - On December 1, 2025, the stock reached a peak increase of 6.72%, bringing the total market capitalization to 4.9 billion [4]. Group 3: Financial Performance - For the first three quarters of the year, the company reported revenue of 1.187 billion, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million, down 12.36% [6]. - In the third quarter, the company achieved revenue of 424 million, a year-on-year increase of 2.67%, and a net profit of 5.98 million, reflecting a significant year-on-year growth of 162.48% [6]. - The adjusted net profit after excluding non-recurring items for the first three quarters was 20.73 million, showing a year-on-year increase of 6.38% [6].